New research at the Icahn School of Medicine at Mount Sinai sheds light for the first time on how depression and emotional resilience operate on a molecular level. The findings, published in the December 4, 2014, issue of Nature, bring fresh perspective to an area that has eluded researchers for decades by outlining the mechanisms within cells that activate depression and laying the groundwork for new treatments. Current drugs for depression focus on neurotransmitters, or communication between cells, but identification of this novel biochemical pathway could pave the way for more effective drugs with very different mechanisms. Read more
Researchers from Icahn School of Medicine at Mount Sinai, participating in the largest genetic study yet on obesity, have helped uncover stronger links between genes and body weight and body fat distribution.
The trailblazing discoveries were published in two companion papers in the February issue of the journal Nature, and were the result of a four-year international research project conducted by the Genetic Investigation of Anthropometric Traits (GIANT) consortium. Other key participating institutions included the Broad Institute of the Massachusetts Institute of Technology and Harvard University, the University of Michigan Health System, and the University of North Carolina School of Medicine. Read more
Joshua D. Rosenberg, MD, Assistant Professor of Otolaryngology at Icahn School of Medicine at Mount Sinai, is one of only a handful of U.S. surgeons who is using an innovative new procedure to restore the ability to smile in patients with facial paralysis.
The procedure, called cranial nerve V and VII transfer, helps to ameliorate the disfiguring effects of severe Bell’s palsy and, to a lesser extent, certain head and neck cancers. It calls for the surgeon to reroute the patient’s robust masseter nerve—which activates the chewing muscles—in order to power the paralyzed facial nerves and restore facial muscle function, specifically the muscles involved in smiling. Read more
Two studies published recently in the Proceedings of the National Academy of Sciences, led by researchers at the Icahn School of Medicine at Mount Sinai, demonstrate how widely used, inexpensive medications to treat osteoporosis, known as bisphosphonates, have the potential to become potent cancer-fighting drugs. Read more
Eric Oermann, MD, a pioneering Neurosurgery second-year resident at Icahn School of Medicine at Mount Sinai, has been named to the fourth annual Forbes “30 Under 30” list as one of the nation’s top Health Care innovators for 2015. According to Forbes, the honorees “reflect the best and the brightest in health care and science.” Read more
Researchers at the Icahn School of Medicine at Mount Sinai have identified 53 drugs approved for use in treating depression, cancer, heart disease, and other illnesses that may also be effective in fighting the Ebola virus. The findings appeared online in the December 17, 2014, journal Emerging Microbes & Infections. Read more
Seminal research led by James Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine, has produced a promising approach to treating patients with graft-versus-host disease (GVHD)—a sometimes fatal complication of bone marrow transplantation in which the donor’s immune cells attack the recipient’s body. Bone marrow transplants are often used to treat patients with leukemia, lymphoma, and other blood diseases. Read more
What are statins?
Statins are a class of cholesterol lowering medication therapies that have been extensively evaluated in controlled clinical trial studies. These medications have been consistently shown to reduce the risk of a first cardiovascular event including heart attack, stroke, and death from heart disease. Also, the drugs can reduce recurrent (two or more) cardiovascular events in people with a prior heart attack, or other acute coronary syndromes that result from a reduction in blood flow to the heart muscle, or stroke. In addition, studies show statins have helped reduce the total amount of deaths worldwide overall from cardiovascular diseases. Read more
For the first time in its 47-year history, the Crohn’s & Colitis Foundation of America has awarded all three of its 2014 annual scientific achievement awards to research and academic luminaries at the Mount Sinai Health System. Read more